Skip to main content
. 2021 Jul 19;59(8):e03003-20. doi: 10.1128/JCM.03003-20

TABLE 2.

Subgroup analysis of eligible studies focused on various types of NAATa

Diagnostic target with microbiological culture reference standard Subgroup NAAT No. of data % sensitivity (95% CI) % specificity (95% CI) PLR (95% CI) NLR (95% CI) DOR (95% CI) AUC (95% CI)
S. aureus In house qPCR 5 97 (93–99) 97 (96–98) 29.0 (11.46–73.16) 0.04 (0.01–0.15) 1,254.4 (159.0–9,899.5) 99 (98–100)
Commercial GeneXpert 4 97 (93–100) 93 (90–95) 15.6 (1.88–129.1) 0.05 (0.01–0.28) 358.0 (43.2–2,968.3) 99 (97–100)
FA-PP 3 100 (90–100) 90 (87–93) 9.6 (4.92–18.56) 0.05 (0.01–0.25) 215.4 (38.93–1,191.8) 98 (96–99)
Unyvero PP 3 81 (69–90) 98 (96–99) 32.6 (5.07–209.43) 0.24 (0.08–0.74) 158.6 (10.61–2,371.3) 97 (96–98)
LAMP 2 53 (36–69) 94 (93–95) 7.88 (5.36–11.57) 0.49 (0.26–0.90) 15.82 (7.13–35.10)
FA-BCID 1 77 (46–95) 100 (91–100) 0.23 (0.09–0.62)
RT-qPCR 1 93 (80–98)
SeptiFast 1 60 (15–95) 83 (71–91) 3.44 (1.40–8.41) 0.48 (0.16–1.43)
ELITE MGB 1 99 (94–100) 100 (88–100) 0.01 (0.0–0.08)
VAPchip 1 86 (64–97) 97 (89–100) 27.43 (6.93–108.51) 0.15 (0.05–0.42)
MRSA In house qPCR 1 100 (90–100) 90 (83–95) 9.83 (5.75–16.81) 0.0
Commercial GeneXpert 5 89 (82–94) 93 (91–95) 13.51 (6.39–28.56) 0.1 (0.0–1,990.93) 279.0 (45.24–1,720.5) 99 (98–100)
FA-PP 2 100 (82–100) 93 (89–95) 11.34 (5.76–22.33) 0.05 (0.01–0.36) 214.63 (27.44–1,678.6)
LAMP 1 42 (31–52) 85 (83–86) 2.69 (2.06–3.5) 0.69 (0.58–0.82)
Unyvero PP 1 0 (0–98) 100 (88–100) 1.0 (1.0–1.0)
a

Abbreviations: −, not estimable; AUC, area under the curve; DOR, diagnostic odds ratio; FA-BCID, FilmArray blood culture identification; FA-PP, FilmArray pneumonia panel; LAMP, loop-mediated isothermal amplification; NAAT, nucleic acid amplification tests; NLR, negative likelihood ratio; PLR, positive likelihood ratio; qPCR, quantitative PCR (real-time PCR); RT-qPCR, reverse transcriptase quantitative PCR.